Your browser doesn't support javascript.
loading
A Mixed-Methods Protocol to Identify Best Practices for Implementing Pharmacogenetic Testing in Clinical Settings.
Sperber, Nina R; Cragun, Deborah; Roberts, Megan C; Bendz, Lisa M; Ince, Parker; Gonzales, Sarah; Haga, Susanne B; Wu, R Ryanne; Petry, Natasha J; Ramsey, Laura; Uber, Ryley.
Afiliação
  • Sperber NR; Department of Population Health Sciences, School of Medicine, Duke University, Durham, NC 27701, USA.
  • Cragun D; Durham VA Health Care System, Durham, NC 27705, USA.
  • Roberts MC; College of Public Health, University of South Florida, Tampa, FL 33612, USA.
  • Bendz LM; UNC Eshelman School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA.
  • Ince P; Center for Medication Policy and Drug Information, Department of Pharmacy, Duke University Hospital, Durham, NC 27710, USA.
  • Gonzales S; Department of Population Health Sciences, School of Medicine, Duke University, Durham, NC 27701, USA.
  • Haga SB; Department of Population Health Sciences, School of Medicine, Duke University, Durham, NC 27701, USA.
  • Wu RR; Department of Medicine, Duke University, Durham, NC 27701, USA.
  • Petry NJ; Durham VA Health Care System, Durham, NC 27705, USA.
  • Ramsey L; Department of Medicine, Duke University, Durham, NC 27701, USA.
  • Uber R; School of Pharmacy, North Dakota State University/Sanford Health Imagenetics, Fargo, ND 58108, USA.
J Pers Med ; 12(8)2022 Aug 13.
Article em En | MEDLINE | ID: mdl-36013262
Using a patient's genetic information to inform medication prescriptions can be clinically effective; however, the practice has not been widely implemented. Health systems need guidance on how to engage with providers to improve pharmacogenetic test utilization. Approaches from the field of implementation science may shed light on the complex factors affecting pharmacogenetic test use in real-world settings and areas to target to improve utilization. This paper presents an approach to studying the application of precision medicine that utilizes mixed qualitative and quantitative methods and implementation science frameworks to understand which factors or combinations consistently account for high versus low utilization of pharmocogenetic testing. This approach involves two phases: (1) collection of qualitative and quantitative data from providers-the cases-at four clinical institutions about their experiences with, and utilization of, pharmacogenetic testing to identify salient factors; and (2) analysis using a Configurational Comparative Method (CCM), using a mathematical algorithm to identify the minimally necessary and sufficient factors that distinguish providers who have higher utilization from those with low utilization. Advantages of this approach are that it can be used for small to moderate sample sizes, and it accounts for conditions found in real-world settings by demonstrating how they coincide to affect utilization.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: J Pers Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research Idioma: En Revista: J Pers Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Suíça